---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-25-000115"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T02:05:29.921877+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Incyte Q3 revenue $1.37B (+20% YoY); raises FY 2025 product revenue guidance to $4.23-4.32B

## Summary
- GAAP diluted EPS $2.11 vs $0.54 YoY; Non-GAAP diluted EPS $2.26 vs $1.07.
- Jakafi net revenue $791M (+7%), Opzelura $188M (+35%), Niktimvo $46M (launch).
- Raised FY 2025 Jakafi guidance to $3.05-3.075B, other oncology to $550-575M.
- FDA approved Opzelura for pediatric atopic dermatitis (age 2+).
- Plan to start registrational program for INCA33890 in MSS CRC in 2026; paused INCA034460, INCB57643, povorcitinib in CSU.

## SEC filing metadata
- accession: 0000879169-25-000115
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916925000115/0000879169-25-000115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916925000115/incy-20251028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-25-000115
- JSON: https://secwatch.observer/filing/0000879169-25-000115.json
- Plain text: https://secwatch.observer/filing/0000879169-25-000115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.